What are the dosing recommendations, indications, contraindications, and alternative therapies for Invanz (ertapenem)?

Invanz (Ertapenem): Dosing, Indications, Contraindications, and Alternatives

Dosing Recommendations

Adults and pediatric patients ≥13 years: 1 gram IV or IM once daily; pediatric patients 3 months to 12 years: 15 mg/kg twice daily (not to exceed 1 g/day). 1

Standard Dosing by Age

• Adults and adolescents ≥13 years: 1 gram IV or IM once daily 1
• Pediatric patients 3 months to 12 years: 15 mg/kg twice daily (maximum 1 g/day) 2, 1
• Infusion duration: 30 minutes for IV administration 1
• Treatment duration: Up to 14 days for IV, up to 7 days for IM 1

Renal Dosing Adjustments

• Creatinine clearance ≤30 mL/min/1.73 m²: Dose reduction to 0.5 g IV daily is required 1
• Hemodialysis patients: The approved 0.5 g daily dose carries a 10% risk of neurotoxicity, particularly in elderly males with dementia or concomitant β-lactam/aminoglycoside/fluoroquinolone use 3
• Alternative hemodialysis dosing (requires further validation): 1 g loading dose, then 0.5 g post-dialysis for 48-hour intervals or 1 g for 72-hour intervals 3
• CVVH patients: 1 g IV daily appears effective and safe 4

Surgical Prophylaxis

• Colorectal surgery: 1 gram single dose given 1 hour prior to incision 1

Administration Considerations

• Do not mix or co-infuse with other medications 1
• Do not use dextrose-containing diluents 1
• IM preparation: Reconstitute with 3.2 mL of 1% lidocaine HCl (without epinephrine); use within 1 hour 1
• IV preparation: Reconstitute with 10 mL Water for Injection or 0.9% Sodium Chloride; dilute to ≤20 mg/mL; use within 6 hours at room temperature or 24 hours refrigerated 1

---

Indications

Ertapenem is indicated for moderate-to-severe community-acquired infections caused by susceptible bacteria, specifically when Pseudomonas aeruginosa and Enterococcus coverage is not required. 2, 1

FDA-Approved Indications

• Complicated intra-abdominal infections 1
• Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis 1
• Community-acquired pneumonia 1
• Complicated urinary tract infections including pyelonephritis 1
• Acute pelvic infections (postpartum endomyometritis, septic abortion, post-surgical gynecologic infections) 1
• Surgical site infection prophylaxis following elective colorectal surgery (adults only) 1

Guideline-Supported Use

Mild-to-Moderate Community-Acquired Intra-Abdominal Infections

Ertapenem is a preferred single-agent option for adults with mild-to-moderate community-acquired intra-abdominal infections, offering narrower spectrum than antipseudomonal agents. 2

• Recommended as monotherapy alongside ticarcillin-clavulanate, cefoxitin, moxifloxacin, or tigecycline 2
• Preferable to regimens with substantial anti-Pseudomonal activity to reduce toxicity risk and antimicrobial resistance 2
• Appropriate for infections derived from distal small bowel, appendix, or colon where anaerobic coverage is required 2

Pediatric Complicated Intra-Abdominal Infections

• Acceptable broad-spectrum option for children with community-acquired infection, alongside carbapenems (imipenem, meropenem), β-lactam/β-lactamase inhibitor combinations, or advanced-generation cephalosporins with metronidazole 2

ESBL-Producing Enterobacterales

• Ertapenem is appropriate for bloodstream infections caused by ESBL-producing Enterobacterales when septic shock is absent, preserving broader-spectrum carbapenems (imipenem, meropenem) for more severe infections. 2, 5
• Recommended for colonized patients undergoing surgery to prevent postoperative infections 2

Off-Label Use: Hidradenitis Suppurativa

• 1 gram IV daily for 12-16 weeks via peripheral intravenous central catheter demonstrated significant improvement in clinical severity and inflammatory markers, with 80% patient satisfaction 6

---

Contraindications

Ertapenem is contraindicated in patients with known hypersensitivity to any component, anaphylactic reactions to β-lactams, or (for IM administration) hypersensitivity to amide-type local anesthetics. 1

Absolute Contraindications

• Known hypersensitivity to ertapenem or any component 1
• Anaphylactic reactions to β-lactams (penicillins, cephalosporins, other carbapenems) 1
• Hypersensitivity to amide-type local anesthetics (for IM administration only, due to lidocaine diluent) 1

Warnings and Precautions

Seizure Risk

• Seizures and CNS adverse events occurred in 0.5% of adult patients during clinical trials, most commonly in those with CNS disorders (brain lesions, seizure history) or compromised renal function. 1
• Close adherence to dosing is critical, especially in patients with predisposing factors 1
• Continue anticonvulsant therapy in patients with known seizure disorders 1
• If seizures occur, evaluate neurologically, initiate/continue anticonvulsants, and consider dose reduction or discontinuation 1
• Hemodialysis patients receiving 0.5 g daily face a 10% neurotoxicity risk, particularly elderly males with dementia or concomitant β-lactam/aminoglycoside/fluoroquinolone use. 3

Valproic Acid Interaction

• Co-administration with valproic acid or divalproex sodium reduces valproic acid concentrations, increasing breakthrough seizure risk; this combination is generally not recommended. 1
• Increasing valproic acid dose may not overcome this interaction 1
• Consider alternative antibacterials (non-carbapenems) for patients with well-controlled seizures on valproic acid 1
• If ertapenem is necessary, add supplemental anticonvulsant therapy 1

Clostridioides difficile-Associated Diarrhea

• Evaluate patients who develop diarrhea during or after treatment 1

Hypersensitivity Reactions

• Serious and occasionally fatal anaphylactic reactions have been reported with β-lactams 1
• More likely in individuals with history of sensitivity to multiple allergens 1
• Inquire about previous hypersensitivity to penicillins, cephalosporins, other β-lactams, and other allergens before initiating therapy 1
• Discontinue immediately if allergic reaction occurs; provide emergency treatment as indicated 1

IM Administration Precautions

• Avoid inadvertent injection into a blood vessel 1

---

Alternative Therapies

For Mild-to-Moderate Community-Acquired Intra-Abdominal Infections

When ertapenem is unavailable or contraindicated, alternative single-agent options include ticarcillin-clavulanate, cefoxitin, moxifloxacin, or tigecycline; combination regimens include metronidazole with cefazolin, cefuroxime, ceftriaxone, cefotaxime, levofloxacin, or ciprofloxacin. 2

Single-Agent Alternatives

• Ticarcillin-clavulanate 2
• Cefoxitin 2
• Moxifloxacin 2
• Tigecycline (concern for overly broad spectrum in mild-moderate infection) 2

Combination Regimens

• Metronidazole plus:
  • Cefazolin, cefuroxime, ceftriaxone, or cefotaxime 2
  • Levofloxacin or ciprofloxacin (only if local E. coli susceptibility ≥90%) 2

Agents NOT Recommended

• Ampicillin-sulbactam: High resistance rates among community-acquired E. coli 2
• Cefotetan and clindamycin: Increasing resistance among Bacteroides fragilis group 2
• Aminoglycosides: Less toxic alternatives available 2

For High-Severity or Healthcare-Associated Intra-Abdominal Infections

When broader coverage is required (critically ill patients, septic shock, high risk for Pseudomonas or Enterococcus), use Group 2 carbapenems (imipenem-cilastatin, meropenem, doripenem) or piperacillin-tazobactam. 2, 5

Preferred Alternatives

• Imipenem-cilastatin 2, 5
• Meropenem 2, 5
• Doripenem 2
• Piperacillin-tazobactam 2

Combination Regimens for Severe Infection

• Third- or fourth-generation cephalosporins (cefotaxime, ceftriaxone, ceftazidime, cefepime) plus metronidazole 2
• Ciprofloxacin plus metronidazole 2
• Aztreonam plus metronidazole 2

When to Escalate from Ertapenem to Group 2 Carbapenems

Escalate to imipenem-cilastatin or meropenem when patients are critically ill with septic shock, have documented or high-risk Pseudomonas aeruginosa or Enterococcus spp., or have nosocomial infections with recent antibiotic exposure or prolonged ICU stay. 5

• Critical illness with severe physiologic disturbance or septic shock 5
• Documented or high-risk Pseudomonas aeruginosa (ertapenem lacks activity) 5
• Documented or high-risk Enterococcus spp. (ertapenem has limited enterococcal activity) 5
• Nosocomial infections with recent antibiotic exposure, prolonged ICU stay, or indwelling devices 5
• Necrotizing soft-tissue or mixed aerobic-anaerobic infections requiring maximal broad-spectrum coverage 5

Antimicrobial Stewardship Considerations

Preserve Group 2 carbapenems (imipenem, meropenem) by preferentially using ertapenem when its spectrum is adequate, thereby conserving antipseudomonal agents for infections that truly require them. 2, 5

• Broad use of ertapenem may hasten emergence of carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter species 2
• Quinolones should not be used unless local E. coli susceptibility ≥90% 2
• Avoid moxifloxacin for B. fragilis infections if quinolone therapy within 3 months (likely resistance) 2

Pediatric Alternatives

For children with severe β-lactam allergies, use ciprofloxacin plus metronidazole or an aminoglycoside-based regimen (ampicillin and gentamicin or tobramycin with metronidazole or clindamycin). 2

Oral Step-Down Therapy

Tebipenem 600 mg PO every 8 hours is under investigation as an oral transition agent following IV ertapenem for ESBL-producing E. coli urinary tract infections, demonstrating bacterial burden reduction and prevention of regrowth in hollow-fiber models. 7

---

Common Pitfalls and Caveats

• Do not use ertapenem for infections likely caused by Pseudomonas aeruginosa, Acinetobacter spp., or Enterococcus spp. 8, 9
• Do not use ertapenem for late-onset nosocomial infections where resistant organisms are likely 8
• Monitor closely for seizures in patients with CNS disorders, renal impairment, or concomitant valproic acid use 1, 3
• Avoid co-administration with valproic acid/divalproex sodium due to risk of breakthrough seizures 1
• Hemodialysis patients require careful monitoring for neurotoxicity with the standard 0.5 g daily dose 3
• Do not co-administer with probenecid (inhibits renal excretion) 1
• Standard 1 g daily dosing may be inadequate in critically ill patients or those with BMI >20 kg/m²; consider shorter dosing intervals or continuous infusion 8
• Empiric enterococcal coverage is not necessary for community-acquired intra-abdominal infections 2
• Empiric antifungal therapy for Candida is not recommended for community-acquired intra-abdominal infections 2